Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Knowledge Among Adolescents With Sickle Cell Disease. (SEXODREP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03235011
Recruitment Status : Completed
First Posted : August 1, 2017
Last Update Posted : February 6, 2019
Sponsor:
Information provided by (Responsible Party):
Adele CARLIER-GONOD, Centre Hospitalier Intercommunal Creteil

Brief Summary:
Evaluation of knowledge about contraception in sickle cell adolescents.

Condition or disease
Sickle Cell Disease

Detailed Description:

Sickle cell teenagers receive regular hospital medical care.

Adolescence is the time when the pathophysiology of the disease is re-explained and when questions around puberty (possibly delayed), sexuality and contraception are discussed.

Sickle cell disease, like any chronic disease, can have repercussion on the development and behavior of young patients.

Knowledge and understanding of young patients with sickle cell disease around these issues may be insufficient.

Layout table for study information
Study Type : Observational
Actual Enrollment : 99 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Knowledge and Practices About Contraception, Sexuality and Transmission Among Adolescents With Sickle Cell Disease.
Actual Study Start Date : March 10, 2017
Actual Primary Completion Date : January 31, 2018
Actual Study Completion Date : January 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control




Primary Outcome Measures :
  1. Score value of the questionnaire on general knowledge on contraception [ Time Frame: at inclusion ]
    questionnaire on general knowledge on contraception rated by 4 questions


Secondary Outcome Measures :
  1. Score value of the questionnaire on specific knowledge on the transmission of the disease [ Time Frame: at inclusion ]
  2. Score value of the questionnaire on the transmission of the disease knowledge [ Time Frame: at inclusion ]
  3. Score value of the questionnaire on specific knowledge about the impact of sickle cell disease on the course of puberty [ Time Frame: at inclusion ]
  4. Score value of the questionnaire onspecific knowledge about the impact of sickle cell disease on the course of sexuality [ Time Frame: at inclusion ]
  5. age of the patient with sickle cell disease [ Time Frame: at inclusion ]
  6. gender of the patient with sickle cell disease [ Time Frame: at inclusion ]
  7. number of hospitalizations of the patient with sickle cell disease [ Time Frame: at inclusion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The teenagers from 14 to 19 years old followed in the STYLE for a sickle cell disease.
Criteria

Inclusion Criteria:

  • Patients with sickle cell disease followed at the CHIC
  • Aged 14 to 19
  • Both sexes

Exclusion Criteria:

  • Neurological disorders that can impede understanding of the questionnaire.
  • Refusal to participate.
  • Not affiliated to social security.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03235011


Locations
Layout table for location information
France
Centre Hospitalier Intercommunal de Créteil
Créteil, Creteil, France, 77500
Sponsors and Collaborators
Adele CARLIER-GONOD

Layout table for additonal information
Responsible Party: Adele CARLIER-GONOD, Peadiatrician, Centre Hospitalier Intercommunal Creteil
ClinicalTrials.gov Identifier: NCT03235011    
Other Study ID Numbers: SEXODREP
First Posted: August 1, 2017    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn